BridgeMD
New treatment option for Deep Vein Thrombosis
Official title Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb
ClinicalTrials.gov ID: NCT05286710
What this study is testing
- What it's testing
- Ipsilateral popliteal venous the most common access for pharmacomechanical thrombectomy (PMT) in the treatment of acute deep venous thrombosis (DVT), but the result was not satisfactory. The investigators adjust the access to improve the thrombus clearance rate and reduce the incidence of post-thrombotic syndrome (PTS).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age between 18-80 years old;
- Acute DVT with clinical symptoms occurred less than 14 days since the onset of disease;
- DVT with thrombosis involving the iliac vein, common femoral vein, distal popliteal vein, and/or calf vein;
- Informed consent signed by patients.
You likely can't join if
- Patients with the previous history of the same side of lower-limb DVT;
- Patients with plasma Creatinine level greater than 180umol/L;
- Patients who are contraindicated to thrombolysis;
- Patients with inferior vena cava thrombosis;
- Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent;
- Patients who have participated in a clinical trial in the past three months;
See the full eligibility criteria
- Age between 18-80 years old;
- Acute DVT with clinical symptoms occurred less than 14 days since the onset of disease;
- DVT with thrombosis involving the iliac vein, common femoral vein, distal popliteal vein, and/or calf vein;
- Informed consent signed by patients.
- Patients with the previous history of the same side of lower-limb DVT;
- Patients with plasma Creatinine level greater than 180umol/L;
- Patients who are contraindicated to thrombolysis;
- Patients with inferior vena cava thrombosis;
- Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent;
- Patients who have participated in a clinical trial in the past three months;
- Women during pregnancy and lactation
- Patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\<2 years);
- Patients with autoimmune thrombopathy or thrombocytopenia (platelets \< 80 10⁹/L);
- Patients who are unable or unwilling to participate in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.